KZR is no longer actively traded. Data shown reflects verified historical relationships.
7Suppliers
4Customers
3Debt Items
5Related Chains

Kezar Life Sciences, Inc. Suppliers

TickerNameConfidenceEvidence
AURINIA-MERGER-SUB-INC AURINIA-MERGER-SUB-INC 90% Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss…
AURINIA-PHARMACEUTICALS-INC AURINIA-PHARMACEUTICALS-INC 90% Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss…
AURINIA-PHARMA-U-S-INC AURINIA-PHARMA-U-S-INC 90% Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss…
BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC BROADRIDGE-CORPORATE-ISSUER-SOLUTIONS-LLC 90% Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss…
ENODIA-THERAPEUTICS-SAS ENODIA-THERAPEUTICS-SAS 90% If Parent receives proceeds in respect of the existing Asset Purchase Agreement, dated March 6, 2026, by and between the Company and Enodia Therapeutics SAS
EVEREST-MEDICINES-II-HK-LIMITED EVEREST-MEDICINES-II-HK-LIMITED 90% If Parent receives proceeds in respect of the existing Collaboration and License Agreement, dated September 20, 2023, by and between the Company and Everest Medicines II (HK) Limited
FORTIS-ADVISORS-LLC FORTIS-ADVISORS-LLC 90% Contingent Value Rights Agreement, dated May 11, 2026, by and among Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., Fortis Advisors LLC and Broadridge Corporate Iss…

Kezar Life Sciences, Inc. Customers

TickerNameConfidenceEvidence
ENODIA ENODIA 92% The Company is also entitled to receive milestone payments from Enodia upon achievement of certain development, regulatory and commercial milestone events related to products developed from the Assets
EVEREST-MEDICINES-II-HK-LIMITED EVEREST-MEDICINES-II-HK-LIMITED 92% Our revenue to date has been generated from the upfront payment pursuant to our collaboration with Everest Medicines II (HK) Limited, or Everest, under our license agreement with them, or the Everest…
MERGER-SUB MERGER-SUB 85% On May 11, 2026, Merger Sub merged with and into the Company
PARENT PARENT 80% Parent accepted for payment all Shares validly tendered (and not validly withdrawn) prior to the expiration of the Offer

Kezar Life Sciences, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KZR-DEBT-10599 Warrants outstanding: 1557153 90% xbrl warrant detail from xbrl 2023-12-31.
KZR-DEBT-10600 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
KZR-DEBT Debt stack $2.3M 90% Market cache reports total debt of $2.3M.

Kezar Life Sciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kezar Life Sciences, Inc..

Kezar Life Sciences, Inc. Ownership

HolderNameConfidenceEvidence
KZR-OWNER-BML-CAPITAL-MANAGEMENT-LLC BML Capital Management, LLC 90% 13F overlay lists BML Capital Management, LLC as top holder; 44 tracked holders.

Kezar Life Sciences, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ENODIA ENODIA 63.48 1 ['receiving']
CR Crane Company 50.00 2
PARENT PARENT 48.00 1 ['receiving']
LEG Leggett & Platt, Incorporated 29.79 2
VALU Value Line, Inc. 22.53 2